Key Segments:
By Product
-
Ozempic
-
Trulicity
-
Mounjaro
-
Wegovy
-
Rybelsus
-
Saxenda
-
Victoza
-
Zepbound
-
Other Products
By Application
-
Type 2 Diabetes Mellitus
-
Obesity
-
Others
By Route of Administration
-
Parenteral
-
Oral
By Distribution Channel
-
Hospital Pharmacies
-
Retail Pharmacies
-
Online Pharmacies
-
Others
Regional Coverage:
North America
-
US
-
Canada
Europe
-
Germany
-
France
-
UK
-
Italy
-
Spain
-
Poland
-
Russia
-
Rest of Europe
Asia Pacific
-
China
-
India
-
Japan
-
South Korea
-
Australia
-
ASEAN Countries
-
Rest of Asia Pacific
Middle East & Africa
-
UAE
-
Saudi Arabia
-
Qatar
-
South Africa
-
Rest of Middle East & Africa
Latin America
-
Brazil
-
Argentina
-
Mexico
-
Colombia
-
Rest of Latin America
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
-
Detailed Volume Analysis
-
Criss-Cross segment analysis (e.g. Product X Application)
-
Competitive Product Benchmarking
-
Geographic Analysis
-
Additional countries in any of the regions
-
Customized Data Representation
-
Detailed analysis and profiling of additional market players
Frequently Asked Questions
Key players include Novo Nordisk A/S, Eli Lilly and Company, Sanofi S.A., AstraZeneca plc, Pfizer Inc., Amgen Inc., and Roche Holding AG, among other pharmaceutical manufacturers.
Continued development of oral GLP-1 formulations and continued development of combination therapies pairing GLP-1 receptor agonism with complementary mechanisms represent the primary opportunities.
Growth is primarily driven by the rising global prevalence of diabetes and obesity combined with expanding therapeutic applications beyond diabetes into obesity and cardiovascular disease.
By Product, Ozempic dominated the market with approximately 32.60% share in 2025, reflecting its established clinical track record, physician familiarity, and broad insurance formulary coverage.
North America dominated the market with approximately 62.60% share in 2025, supported by strong prevalence of obesity and diabetes and a favorable insurance reimbursement environment.
